Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16% [14] - For the full year 2025, total revenue was $151.8 million, a decrease of approximately 15.8% compared to fiscal 2024 [15] - Adjusted EBITDA for Q4 was $2.5 million, representing a margin of 7.4%, an increase of $0.6 million and 2.8% margin expansion year-over-year [15] - Full year adjusted EBITDA was approximately $15 million, resulting in an adjusted EBITDA margin of approximately 10% [15] Business Line Data and Key Metrics Changes - The company reported improvements in lead and consult volumes, contributing to better revenue trends moving into 2026 [5] - Over 100 skin removal surgeries were completed in Q4 2025, with expectations for ramp-up in 2026 as capabilities expand across all locations [8] Market Data and Key Metrics Changes - The skin tightening and skin removal market is projected to be as large as fat removal, representing a long-term sales opportunity exceeding $100 million [7] - The percentage of patients using financing for procedures was approximately 50% [14] Company Strategy and Development Direction - The company is focusing on introducing new services to capture the GLP-1 market opportunity, enhancing sales and marketing strategies, and maintaining strong financial discipline [6] - Strategic exit from the only clinic outside North America was made to streamline operations [5] - The company aims to build on momentum and drive disciplined growth to create shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a year of rebuilding and transformation, with same-store sales improving from down 22% at the start of 2025 to positive in February 2026 [5] - The company expects revenue in 2026 to range from $151 million to $157 million, reflecting approximately 3% comparable growth [17] - Management acknowledged the need to monitor the helium plasma supply situation due to geopolitical issues affecting skin tightening procedures [18] Other Important Information - The company paid down $19 million of debt in 2025, with gross debt outstanding at $56 million at year-end [16] - Cash flow from operations for the year was $3.1 million, down from $11.4 million in fiscal 2024 [17] Q&A Session Summary Question: Guidance for 1Q indicates a slight decline year-over-year, while full year 2026 revenue is expected to be up slightly. What is causing this change in seasonality? - Management indicated that trends have improved significantly, and they are focused on execution to ensure they meet their numbers [22] Question: Can the company isolate market trends for the core business outside of GLP-1 related procedures? - Management noted that the core business around body contouring and fat removal is holding steady, with GLP-1 being the next wave of change [23] Question: What feedback has the company received regarding excisional procedures from the pilot phase? - Management reported excellent results from patients and comfort from surgeons, with plans to ramp up procedures as the year progresses [27] Question: How should capital allocation be viewed going forward regarding debt pay down versus business investment? - Management emphasized the priority of maintaining a healthy balance sheet while also investing back into the business for growth initiatives [29]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16% [14] - For the full year 2025, total revenue was $151.8 million, a decrease of approximately 15.8% compared to fiscal 2024 [15] - Adjusted EBITDA for Q4 was $2.5 million, representing a margin of 7.4%, an increase of $0.6 million and 2.8% margin expansion year-over-year [15] - Full year adjusted EBITDA was approximately $15 million, resulting in an adjusted EBITDA margin of approximately 10% [15] Business Line Data and Key Metrics Changes - The company reported improvements in same-store sales, which improved from down 22% at the start of 2025 to positive growth in February 2026 [5] - Over 100 skin removal surgeries were completed in Q4 2025, with expectations for ramp-up in 2026 as capabilities expand across all locations [8] Market Data and Key Metrics Changes - The skin tightening and skin removal market is projected to be as large as fat removal, representing a long-term sales opportunity exceeding $100 million [7] - The percentage of patients using financing for procedures was approximately 50% [14] Company Strategy and Development Direction - The company is focusing on introducing new services to capture the GLP-1 market opportunity, enhancing sales and marketing strategies, and maintaining strong financial discipline [6] - Strategic exit from the only clinic outside North America was made to streamline operations [5] - The company aims to build on momentum and drive disciplined growth to create shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a year of rebuilding and transformation, with a focus on stabilizing the core business and improving operational performance [5] - For 2026, the company expects revenue in the range of $151 million to $157 million, reflecting approximately 3% comparable growth [17] - Management expressed confidence in the full-year outlook, citing improved trends and a focus on execution [21] Other Important Information - The company paid down $19 million of debt in 2025, with gross debt outstanding at $56 million at year-end [16] - A reconciliation matter related to intercompany transactions was identified, leading to immaterial changes in prior year balances, but had no impact on revenue or cash [13] Q&A Session Summary Question: Guidance for 1Q indicates a slight decline year-over-year, while full year 2026 revenue is expected to be up slightly. What is causing this change in seasonality? - Management acknowledged improved trends and emphasized the need for consistent results to meet guidance [21] Question: Can the company isolate market trends for the core business outside of GLP-1 related procedures? - Management noted that the core business around body contouring and fat removal is holding steady, with GLP-1s expected to drive future demand [22] Question: Feedback on excisional procedures pilot and plans for broader rollout? - Management reported excellent results from the pilot, with positive feedback from patients and surgeons, and plans to ramp up procedures throughout the year [25] Question: Thoughts on capital allocation and debt pay down strategy? - Management indicated that the priority remains on maintaining a healthy balance sheet, with plans to refinance debt while investing back into the business [28]

Core Insights - The company's growth in the fourth quarter was primarily driven by its branded aesthetic center business, with revenue from aesthetic treatment services reaching RMB 248.1 million, a year-over-year increase of 205.3%, marking over 50% of total revenue for the first time [1][7] - Fourth-quarter revenue was reported at RMB 460.7 million, reflecting a year-over-year growth of 24.8%, and setting a record-high quarterly revenue for the company [2][7] - The company is focusing on scaling its aesthetic center network while improving profitability and operational efficiency, indicating a strategic turning point for 2026 [5] Financial Performance - Revenue from aesthetic treatment services significantly contributed to overall growth, with verified treatment visits exceeding 125,000, up 178% year-over-year, and verified aesthetic treatments performed exceeding 289,400, up 168% year-over-year [9][7] - The company plans to open at least 35 new centers in 2026 while balancing expansion with profitability [12][22] - By the end of 2025, the company operated 49 laser medical aesthetic centers across 15 major cities, with a net addition of 10 centers during the quarter [8][7] Operational Improvements - The full-time physician team grew to 211, representing a 41% increase from the previous quarter, with all physicians having public-hospital backgrounds and passing internal certification [14][6] - Management reported that 25 centers achieved profitability in Q4, with 39 centers generating positive operating cash flow [12][7] - The average revenue per center nearly doubles as locations progress from growth phase to maturity, indicating a built-in revenue growth driver [10][11] Market Dynamics - The medical aesthetic industry in China is undergoing structural adjustments, with a shift towards value-driven consumer behavior, creating opportunities for companies that can deliver trusted services [4] - The company is enhancing its supply chain capabilities, working with 18 top-tier domestic device suppliers and 42 upstream partners for injectables, which improves product selection and procurement costs [17][18] Future Outlook - The company guided first-quarter 2026 aesthetic treatment services revenue to be between RMB 268 million and RMB 278 million, representing year-over-year growth of 171.2% to 181.3% [22] - Management emphasized a referral-driven approach and membership benefits as key drivers for customer acquisition, maintaining annual customer acquisition costs below 10% of revenue [24] - Centers in second-tier cities have shown good growth, with revenue levels approaching those of first-tier cities, indicating potential for further expansion in these markets [25]

Core Insights - So-Young International Inc. reported strong financial results for the fourth quarter and fiscal year 2025, highlighting significant growth in aesthetic treatment services and a reduction in net losses compared to the previous year. Financial Highlights - Total revenues for Q4 2025 were RMB 460.7 million (US$ 65.9 million), a 24.8% increase from RMB 369.2 million in Q4 2024 [4][11] - Aesthetic treatment services revenues reached RMB 248.1 million (US$ 35.5 million), up 205.3% from RMB 81.3 million in the same period of 2024 [15] - The net loss attributable to So-Young was RMB 108.8 million (US$ 15.6 million), significantly reduced from RMB 607.6 million in Q4 2024 [4][19] - Non-GAAP net loss for Q4 2025 was RMB 93.4 million (US$ 13.2 million), compared to RMB 53.2 million in Q4 2024 [22] Operational Highlights - The number of verified treatment visits to branded aesthetic centers exceeded 125,000 in Q4 2025, compared to approximately 45,000 in Q4 2024 [4] - Active users reached over 171,000, a significant increase from approximately 52,700 in the same period of 2024 [4] - The company operated 49 branded aesthetic centers as of December 31, 2025, with 25 centers achieving profitability in Q4 [4][10] Fiscal Year 2025 Overview - Total revenues for fiscal year 2025 were RMB 1,523.4 million (US$ 217.8 million), a 3.9% increase from RMB 1,466.7 million in fiscal year 2024 [7][23] - The net loss for fiscal year 2025 was RMB 242.3 million (US$ 34.6 million), down from RMB 589.5 million in the prior year [14][27] - Non-GAAP net loss for fiscal year 2025 was RMB 217.1 million (US$ 31.0 million), compared to RMB 4.7 million in fiscal year 2024 [28] Cost and Expense Management - Cost of revenues for Q4 2025 was RMB 255.9 million (US$ 36.6 million), a 67.2% increase from RMB 153.1 million in Q4 2024 [14] - Total operating expenses decreased by 59.8% to RMB 327.7 million (US$ 46.9 million) in Q4 2025 from RMB 815.2 million in Q4 2024 [18] - Sales and marketing expenses increased by 25.8% to RMB 168.7 million (US$ 24.1 million) in Q4 2025, primarily due to branding and user acquisition activities [21] Business Outlook - For Q1 2026, So-Young expects aesthetic treatment services revenues to be between RMB 268.0 million (US$ 38.3 million) and RMB 278.0 million (US$ 39.8 million), representing a projected increase of 171.2% to 181.3% from Q1 2025 [30]

Core Insights - Sisram Medical reported solid growth in 2025, driven by strong performance in international markets and an accelerating injectables business [1] - The company achieved a revenue of US$365.3 million, marking a 4.7% year-on-year increase, with injectables revenue soaring by 185.6% to US$28.0 million [6] - The company is focusing on building an integrated medical aesthetics ecosystem, enhancing its product offerings and expanding its market presence [8][9] Financial Highlights - Revenue for the year ended December 31, 2025, was US$365.3 million, a 4.7% increase year-on-year [6] - Injectables revenue reached US$28.0 million, reflecting a significant increase of 185.6% year-on-year [6] - Gross profit margin decreased to 58.9% from 62.1% in 2024, while net profit decreased by 13.1% to US$25.0 million [6] Key Achievements - The energy-based device (EBD) portfolio reinforced Sisram's leadership in the global aesthetics market, with Alma Harmony receiving multiple awards [4] - DAXXIFY achieved regulatory approval and initial clinical applications in China, with over 10,000 units shipped [5] - The company launched Universkin by Alma, an AI-powered personalized skincare platform, enhancing its service offerings [7] Market Expansion - International markets (excluding North America) grew by 20.1% year-on-year, with APAC revenue increasing by 26.9% to US$147.4 million [6] - Revenue in Europe and the Middle East and Africa was US$56.4 million and US$36.4 million, representing increases of 11.7% and 5.3% year-on-year, respectively [6] - North America revenue decreased by 19.2% to US$111.0 million [6] Strategic Outlook - Sisram plans to establish a manufacturing facility in China to support regional R&D and production [8] - The company aims to prioritize the commercialization of DAXXIFY in mainland China and advance regulatory approvals for additional injectables [9] - Sisram will explore strategic M&A opportunities to enhance its ecosystem and innovation capabilities [9]

Core Insights - Aphranel, a regenerative medical aesthetics brand from China, has been recognized in the Third Forbes China Beauty 100 list, highlighting its innovation and growth potential in the beauty and medical aesthetics sector [1] Group 1: Company Overview - Aphranel is under the company Shanghai Moyang Biotechnology and focuses on calcium hydroxyapatite (CaHA) regenerative materials for medical aesthetics [1] - The brand emphasizes long-term product development through scientific research and clinical validation, investing in material optimization and safety data [1] Group 2: Product Development - Aphranel's CaHA facial injectable filler consists of 30% CaHA microspheres and 70% CMC gel carrier, designed to provide immediate support while promoting collagen regeneration [1] - The product utilizes patented technologies, including ACD-MT™ for microspheres and PCD-ETT™ for the gel, ensuring effective tissue integration and stable support during injection [1] Group 3: Brand Philosophy - The "Aphranel Poetics of Time" brand philosophy promotes the idea that aesthetic treatments should align with natural biological processes for sustainable outcomes [1] - The company invests in physician education initiatives, including academic exchanges and clinical support, to enhance physician skills and patient outcomes [1] Group 4: Industry Trends - As China's medical aesthetics sector becomes more regulated, brands that prioritize compliance, clinical data, and professional education are gaining recognition [1] - Aphranel plans to increase investments in materials research, clinical collaboration, and education to strengthen the link between scientific innovation and clinical practice [1]

Core Insights - The Beauty Health Company is positioned for long-term growth in the professional skin health market, leveraging its established brand and technology to enhance commercial execution and operational discipline [1][5][24]. Financial Performance - In Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, with consumables revenue increasing to $57.7 million, up 1.7% from the previous year [11][29]. - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [11]. - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4%, driven by a favorable shift towards consumables revenue [12][30]. - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [12][31]. - For the full year 2025, net sales totaled $300.8 million, down from $334.3 million in 2024, with adjusted EBITDA increasing to $45.1 million from $12.3 million [27]. Market Trends - The U.S. medspa market has expanded significantly, growing from approximately 1,600 locations in 2010 to over 13,000 today, indicating strong consumer interest in skin health [6]. - Consumers are increasingly investing in skin health as a lifestyle choice, seeking clinically proven outcomes and natural results [6][9]. - The market is shifting towards combination therapies and clinically validated results, favoring companies with strong provider education and recurring revenue models [15][16]. Strategic Initiatives - The company aims to enhance its commercial model by focusing on device utilization rather than just placement, which is expected to drive long-term growth [10][14]. - Key priorities include improving salesforce excellence, marketing discipline, and focused innovation to strengthen the installed base and expand the role of HydraFacial in provider practices [17][20][22]. - The company plans to launch a next-generation HydraFacial system by 2028, aimed at enhancing the value proposition for providers [57]. Guidance and Outlook - For 2026, the company expects revenue to be in the range of $285 million to $305 million, with positive adjusted EBITDA of $35 million to $45 million, reflecting a focus on execution and stabilization [32][33]. - The first quarter of 2026 is projected to have revenue of $63 million to $68 million, typically the lowest revenue quarter due to seasonal dynamics [35]. - The company anticipates returning to growth in 2027 as operational changes take effect and innovation scales [34][37].

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [10] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [10] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [10] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [11] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, marking a significant margin expansion [11] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with adjusted EBITDA increasing to $45.1 million from $12.3 million [21][22] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in the global install base [12] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [12] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [7] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [7][8] Company Strategy and Development Direction - The company aims to shift from a device placement model to a device utilization model to drive long-term growth [9] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [14] - The company plans to enhance its commercial model by improving provider education and marketing strategies [16][18] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the demand for non-invasive treatments, despite macroeconomic pressures affecting capital equipment sales [12][39] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half [25][28] - The company expects to return to growth in 2027 as operational changes take effect [19][28] Other Important Information - The company has strengthened its balance sheet and improved its cost structure, exiting 2025 in a stronger position than the previous year [20] - The average spend per treatment in the U.S. for consumables is up 10% year-over-year, driven by premium boosters [62] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D [32][33] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results; the aesthetics category has faced pressure due to credit tightness [38][39] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with expectations to hold flat year-over-year; marketing strategies are being adjusted to target new demographics [46][49] Question: New system launch timeline and features - The next-generation HydraFacial is planned for launch in 2028, aimed at providing compelling reasons for upgrades [55] Question: Consumables performance and pricing strategy - A 5% price increase on consumables was well-received, and the company is evaluating overall pricing strategy moving forward [76]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [10] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [10] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [10] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [11] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [11] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [21] Business Line Data and Key Metrics Changes - The installed base of systems reached over 36,000 globally, with more than 1,000 devices placed in Q4 [12] - The capital equipment segment continues to face pressure, consistent with broader macroeconomic conditions [10] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating significant market expansion [7] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers [7] Company Strategy and Development Direction - The company aims to shift from a device placement model to a device utilization model to drive long-term growth [9] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [14] - The company plans to enhance its commercial model by improving provider education and marketing strategies [16][17] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [12] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half [19][25] - The company expects to return to growth in 2027 as operational changes take effect [28] Other Important Information - The company has strengthened its balance sheet and improved its cost structure, exiting 2025 as a stronger entity [20] - Adjusted EBITDA for the full year increased significantly to $45.1 million from $12.3 million in the prior year [21] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with adjusted EBITDA slightly below 2025 due to reinvestment in R&D [32][33] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points [37] - The medical segment continues to grow, driven by med spas using HydraFacial to attract patients [39] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with expectations to hold flat year-over-year [44] - The company is addressing the needs of new demographics entering the category, focusing on outcome-driven protocols [47] Question: New system launch timeline and features - The next-generation HydraFacial is planned for launch in 2028, aimed at providing compelling reasons for upgrades [53] Question: Pricing strategy and consumable utilization - A 5% price increase on consumables was well-received, with no significant complaints [73] - Providers who understand how to prescribe boosters use them three times more than those who do not [74]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [9][21] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [9] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [9] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [10][22] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [10][23] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [20] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in its global install base [11] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [11] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [6] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [6][7] Company Strategy and Development Direction - The company aims to shift its model from device placement to device utilization, focusing on unlocking the economic potential of its installed base [8] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [12][14] - The company plans to enhance its product ecosystem and strengthen its market position through disciplined innovation and targeted marketing efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [11] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half as execution initiatives take hold [17][24] - The company expects to return to growth in 2027, driven by operational changes and innovation [17][26] Other Important Information - The company ended 2025 with approximately $232.7 million in cash equivalents, a decrease from $370.1 million in 2024, primarily due to debt restructuring [21] - The company is focusing on improving its balance sheet and financial discipline, which has contributed to its stabilization [10][18] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D for future innovation [30][31] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points, impacting procedure volume and device placements [36][37] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with a focus on restructuring sales and customer service teams to better support smaller accounts [41][43] - The company is addressing the needs of new demographics, including men and Gen Z, by positioning HydraFacial as a lifestyle routine [45][46] Question: New system launch timeline and additional services - The next-generation HydraFacial is in early development, with a planned launch in 2028, aimed at providing compelling reasons for upgrades [51][52] Question: Consumables performance and pricing strategy - The company successfully implemented a 5% price increase on consumables without significant pushback, and is evaluating overall pricing strategy moving forward [74]